| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/29/2004 | WO2001079274A8 Tuberculosis antigens and methods of use thereof |
| 04/29/2004 | WO1994004185A3 Method of inhibiting reduction of disulfide bonds |
| 04/29/2004 | WO1991013987A3 Cdna coding for the gene n of the viral haemorrhagic septicaemia virus and utilizations thereof |
| 04/29/2004 | WO1991000348A3 Modified vp1/p2a regions of the rhinoviral system |
| 04/29/2004 | US20040083496 Genetic engineered polypeptides; incubation, amplification |
| 04/29/2004 | US20040082934 Method of controlling pharmacokinetics of immunomodulatory compounds |
| 04/29/2004 | US20040082764 Complex of antibodic and antibiotic with carrier |
| 04/29/2004 | US20040082763 Diagnosis, therapy of Alzheimer's disease; synthetic antibody |
| 04/29/2004 | US20040082758 Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated |
| 04/29/2004 | US20040082634 Using allantoin; skin disorders, antiulcer agents, antiinflammatory agents |
| 04/29/2004 | US20040082538 Adjuvants and processes to induce a specific type of immune response |
| 04/29/2004 | US20040082532 Antifungal therapeutic targets |
| 04/29/2004 | US20040082531 Containing a transcription regulatory sequence derived from Human Cytomegalovirus major immediate early gene that includes exon 1, but not intron A; use of such vectors in vaccine and pharmaceutical compositions and gene therapy |
| 04/29/2004 | US20040082530 Nucleic acid immunization |
| 04/29/2004 | US20040082512 Drugs for treatment of inflammation/blood brain barrier degradation |
| 04/29/2004 | US20040082510 Pyk2 phosphorylation by her3 induces tumor invasion |
| 04/29/2004 | US20040082506 For treating hypophosphatemic rickets/osteomalacia/ osteoporosis/renal osteodystrophy/dialysis-associated bone diseases |
| 04/29/2004 | US20040082067 Immunology, diagnosis, therapy; complex of carbohydrate and protein; immobilization |
| 04/29/2004 | US20040082065 Cascading priming cells; stimulating lymphocytes; incubation |
| 04/29/2004 | US20040082033 Genetic engineering; neutralizing antibodies; vaccines |
| 04/29/2004 | US20040082002 Genetic engineering; screening antagonist; medical diagnosis using antibodies |
| 04/29/2004 | US20040081998 Novel carboxylesterase nucleic acid molecules, proteins and uses thereof |
| 04/29/2004 | US20040081986 Genetic engineering; libraries; lung cells; hybrids; process control; controlling activation; antiinflammatory agents; autoimmune diseases; infections; bone disorders; anticancer agents |
| 04/29/2004 | US20040081968 Method and mixture for curing autoimmune disease |
| 04/29/2004 | US20040081686 Use of particle vectors in immunomodulation |
| 04/29/2004 | US20040081667 Compositions and methods for treating and preventing infection |
| 04/29/2004 | US20040081666 Cattle reproductive disease vaccines |
| 04/29/2004 | US20040081665 Chlorella preparations exhibiting immunomodulating properties |
| 04/29/2004 | US20040081662 Vaccine |
| 04/29/2004 | US20040081661 Papillomavirus truncated L1 protein and fusion protein constructs |
| 04/29/2004 | US20040081658 Epitopes involved in the immune response to human papillomavirus; induction and/or enhancement of a T cell response directed towards an antigen, using peptides comprising specific epitopes for said antigen |
| 04/29/2004 | US20040081657 Prevention and treatment of amyloidogenic disease |
| 04/29/2004 | US20040081656 Vaccine based on fact that a significant proportion of canine and feline tumours express an oncofetal leucine-rich glycoprotein, known as "5T4" |
| 04/29/2004 | US20040081655 Methods and compositions comprising polycationic compounds |
| 04/29/2004 | US20040081654 Use of plant oil-bodies in vaccine delivery systems |
| 04/29/2004 | US20040081651 Crystal structure of the complex between one such antibody and the alpha 1-I domain of VLA-1, and to the use of this structural information for computational drug design |
| 04/29/2004 | US20040081650 Inflammatory mediator antagonists |
| 04/29/2004 | US20040081646 Group B Streptococcal phage lysin |
| 04/29/2004 | US20040081638 Delivery of disease control in aquaculture and agriculture using nutritional feeds containing bioactive proteins produced by viruses |
| 04/29/2004 | US20040081636 Genetic engineering; polynucleotides |
| 04/29/2004 | DE10294485T5 Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind Mnk homologous proteins with kinase, that are involved in the regulation of energy homeostasis and the metabolism organelle |
| 04/29/2004 | DE10248301A1 Herstellung eines Lebend-Impfstoffes gegen Influenza-Viren Preparation of a live vaccine against influenza viruses |
| 04/29/2004 | CA2649821A1 Polynucleotide sequences encoding .delta.bcl-2 for preventing and treating autoimmune diseases |
| 04/29/2004 | CA2504656A1 Therapeutic adjuvant |
| 04/29/2004 | CA2502414A1 Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof |
| 04/29/2004 | CA2502250A1 Methods using gene trapped stem cells for marking pathways of stem cell differentiation and making and isolating differentiated cells |
| 04/29/2004 | CA2502211A1 Azo compounds for type i phototherapy |
| 04/29/2004 | CA2501994A1 Use of poly-alpha2,8-sialic acid mimetic peptides to modulate ncam functions |
| 04/29/2004 | CA2500336A1 Improved immunotherapy |
| 04/29/2004 | CA2497262A1 Buccal polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 04/29/2004 | CA2483925A1 Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines comprising heat shock protein-peptide complexes or alpha-2-macroglobulin-peptide complexes |
| 04/28/2004 | EP1413581A1 Rapamycin derivatives |
| 04/28/2004 | EP1413316A1 Bifunctional conjugates or fusion proteins |
| 04/28/2004 | EP1412757A2 Method for identification of proteins from intracellular bacteria |
| 04/28/2004 | EP1412754A1 Diagnostic methods and agents |
| 04/28/2004 | EP1412502A2 Use of clya hemolysin for excretion of fusion proteins |
| 04/28/2004 | EP1412501A1 Hepatitis b virus pre-s1 derived synthetic polypeptides and uses thereof |
| 04/28/2004 | EP1412499A2 Cytokine polypeptides |
| 04/28/2004 | EP1412498A2 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby |
| 04/28/2004 | EP1412492A2 Regulator of calcineurin |
| 04/28/2004 | EP1412486A2 Method for virus propagation |
| 04/28/2004 | EP1412485A1 Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| 04/28/2004 | EP1412482A2 Uses of opg ligand to modulate immune responses |
| 04/28/2004 | EP1412477A2 GPCs AS MODIFIERS OF THE IRRTK AND P21 PATHWAYS AND METHODS OF USE |
| 04/28/2004 | EP1412389A1 Binding agents with differential activity |
| 04/28/2004 | EP1412388A1 Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
| 04/28/2004 | EP1412387A2 Transporters and ion channels |
| 04/28/2004 | EP1412381A2 Meningococcus adhesins nada, app and orf40 |
| 04/28/2004 | EP1412379A2 Antigenic polypeptides |
| 04/28/2004 | EP1411990A2 Modulation of antibody formation in mammals, applicability in gene therapy and animal model generation |
| 04/28/2004 | EP1411987A2 Targeted polymeric delivery systems |
| 04/28/2004 | EP1411983A1 Bispecific antibodies that bind to vegf receptors |
| 04/28/2004 | EP1411982A1 Modulators of p-selectin glycoprotein ligand 1 |
| 04/28/2004 | EP1411981A2 Polyvalent vaccine against diseases caused by papilloma viruses, method for the production and the use thereof |
| 04/28/2004 | EP1411980A2 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection |
| 04/28/2004 | EP1411979A1 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv |
| 04/28/2004 | EP1411978A1 Botulinum toxin in the treatment or prevention of acne |
| 04/28/2004 | EP1411977A1 Composition containing bacterial antigens, used for the prophylaxis and the treatment of allergic diseases |
| 04/28/2004 | EP1411976A2 Novel vaccine for prophylaxis and therapy in veterinary and human medicine |
| 04/28/2004 | EP1411975A1 Methylation of histone h4 at arginine 3 |
| 04/28/2004 | EP1411974A2 Materials and methods relating to improved vaccination strategies |
| 04/28/2004 | EP1411970A2 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 04/28/2004 | EP1411966A2 Method for treating secondary tissue degeneration associated with central nervous system injury |
| 04/28/2004 | EP1411962A2 Monoclonal antibody therapy for pancreas cancer |
| 04/28/2004 | EP1411951A2 Enteral compositions for the prevention and/or treatment of sepsis |
| 04/28/2004 | EP1411907A1 Inhibitors of hb-egf (erbb) receptors for treating myeloma |
| 04/28/2004 | EP1411905A1 Sustained release delivery system |
| 04/28/2004 | EP1411770A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 04/28/2004 | EP1382688A9 Screening method |
| 04/28/2004 | EP1307213B1 Chlorella preparations exhibiting immunomodulating properties |
| 04/28/2004 | EP1255559B1 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 04/28/2004 | EP1058555B1 Costimulatory blockade and mixed chimerism in allotransplantation |
| 04/28/2004 | EP0913157B1 A composite vaccine which contains antigen, antibody and recombinant dna and its preparing method |
| 04/28/2004 | EP0856054B1 Monoclonal antibody br110 and uses thereof |
| 04/28/2004 | EP0784682B1 Novel ectoparasite saliva proteins and apparatus to collect such proteins |
| 04/28/2004 | EP0626861B2 Treatment for asthma |
| 04/28/2004 | CN1492930A Anti-interferon-šŒantibodies |
| 04/28/2004 | CN1492926A Preferred segments of neural thread protein and methods of using the same |
| 04/28/2004 | CN1492923A 减毒的活疫苗 Attenuated live vaccine |
| 04/28/2004 | CN1492879A Protein tau |